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Abstract
The DNA-based techniques used to detect bacteria in clinical
samples are unable to discriminate between live bacteria, dead
bacteria, and extracellular DNA. This failure to limit analysis to
viable bacterial cells represents a signiﬁcant problem, leading to
false-positive results, as well as a failure to resolve the impact of
antimicrobial therapy. The use of propidium monoazide treat-
ment signiﬁcantly reduces the contribution of dead cells and
extracellular DNA to such culture-independent analyses. Here,
the increased ability to resolve the impact of antibiotic therapy
on Pseudomonas aeruginosa load in cystic ﬁbrosis respiratory
samples reveals statistically signiﬁcant changes that would other-
wise go undetected.
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Culture-independent strategies as applied for the detection
of bacteria in clinical samples are being employed increasingly
and for an ever-widening set of sample types. The application
of these techniques has, in many cases, been a response to
the limitations of traditional culture-based microbiological
diagnostics, e.g. in the identiﬁcation of species refractory to
culture. However, basing detection and characterization on
bacterial DNA ‘signatures’ has a fundamental ﬂaw that is not
present in traditional culture-based analysis. This ﬂaw lies in
the inability of DNA-based analyses to differentiate between
signals from live bacteria, DNA in dead bacteria, or DNA
present in an extracellular form. In turn, basing analysis on
DNA signals alone results in an increased number of false-
positive results [1–3], or an overestimation of bacterial num-
bers [4]. Furthermore, it may fail to detect the impact on
bacterial populations of antimicrobial therapy. Both of these
scenarios have clear clinical signiﬁcance.
Here, we propose a strategy to circumvent this problem.
Through the use of propidium monoazide (PMA) treatment
prior to the extraction of DNA from clinical samples, DNA
derived from non-viable cells, or extracellular DNA, is
excluded from subsequent PCR-based analysis. PMA, a mem-
brane-impermeant dye that selectively penetrates the com-
promised membranes of dead cells, intercalates into DNA.
Through exposure to light, the PMA becomes covalently
cross-linked to the DNA, and this, in turn, renders the DNA
unavailable for subsequent PCR ampliﬁcation. The use of
PMA in this way was developed in the ﬁeld of environmental
microbial ecology [4,5], and has been shown to be effective
in clinical situations [6,7]. PMA treatment, performed as
described here, has prevented ampliﬁcation from non-viable
cells of a number of clinically important pathogens, including
methicillin-resistant Staphylococcus aureus, Escherichia coli, and
Acinetobacter baumanii (data not shown).
In addition, the failure to limit analysis to viable cells has
clear relevance for bacterial quantiﬁcation by real-time PCR
(RT-PCR). In this context, the presence of non-viable bacte-
ria could lead to a signiﬁcant overestimation of the number
of cells present [8]. This represents a major impediment to
the use of such techniques to track reductions in bacterial
cell numbers that result from antibiotic therapy, and thereby
assess the efﬁcacy of such treatments. This is likely to be
particularly problematic for those situations in which there is
poor clearance of material from the site of infection.
Here, we demonstrate the impact of PMA treatment of
cystic ﬁbrosis (CF) sputum samples on RT-PCR quantiﬁcation
of the load of Pseudomonas aeruginosa during antibiotic ther-
apy. This study, undertaken with local ethical approval from
Southampton and South West Hampshire Research Ethics
Committee (06/Q1704/26), used sputum samples collected
from 14 adult CF patients before and after a 14-day period
of antibiotic therapy given to treat exacerbations of pulmo-
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nary symptoms. Within the patient group, a number of
different antibiotics effective against P. aeruginosa were used,
including intravenous ceftazidime, tobramycin, gentamicin,
colomycin, meropenem, and oral ciproﬂoxacin, in a number
of antibiotic combinations.
PMA treatment was performed as described by Rogers
et al. [7], with DNA extraction as described by Rogers et al.
[9]. All RT-PCR analyses were performed in triplicate, and
the load of P. aeruginosa was determined using a Taqman
assay that ampliﬁed a 65-bp fragment of the regA gene [10].
Load per millilitre was determined by comparison with stan-
dard curves generated from P. aeruginosa (ATCC 27853)
cells grown in nutrient broth at 37C for 16 h, and CFU/mL
were estimated by incubation of dilutions (n = 4) on Columbia
Blood Agar at 37C for 24 h, followed by colony counts.
Fig. 1 shows the impact of antibiotic therapy on estimates
of P. aeruginosa load in sputa over the 14-day treatment per-
iod, quantiﬁcation being performed with and without PMA
treatment. Where PMA treatment was not used, no signiﬁ-
cant decrease in the P. aeruginosa load during the treatment
period was observed; P. aeruginosa levels were seen to
decrease in six patients and increase in eight. In comparison,
when PMA treatment was used, P. aeruginosa load was seen
to decrease over the treatment period in 13 of the 14
patients (a slight increase was observed in one patient, with
levels of 2.7 · 108 CFU/mL before and 2.9 · 108 CFU/mL
after treatment.
A pairwise comparison of the P. aeruginosa load before
and after antibiotic therapy in the PMA-treated samples
showed that this decrease was signiﬁcant (p 0.05, paired
t-test), with mean values of 2.2 · 109 CFU/mL (standard
deviation 4.5 · 109) before antibiotic treatment and
9.7 · 107 CFU/mL (standard deviation 2.6) after it. Further-
more, the P. aeruginosa load in PMA-treated samples was
signiﬁcantly lower after the antibiotic treatment than it was
in matched, untreated samples (p 0.02, paired t-test). In
addition, P. aeruginosa log-phase cells were used to spike spu-
tum aliquots. The addition of 108 CFU of either live or heat-
killed cells resulted in a proportional increase in CFU/mL
estimations based on Ct values when no PMA treatment was
used, or when PMA treatment was used with live P. aerugin-
osa but not with heat-killed P. aeruginosa cells and PMA
treatment (data not shown).
These ﬁndings strongly support the contention that non-
viable cells can contribute signiﬁcantly to the quantitative
process. In the speciﬁc scenario examined here, airway
secretions from CF patients are poorly cleared [11,12], with
the presence of non-viable cells in the airways being likely to
result in a signiﬁcant overestimation of bacterial load, and
masking of the impact of antibiotic therapy. These data sug-
gest that determining the impact of antibiotic treatments
in vivo by using nucleic acid-based strategies such as RT-PCR
can only be achieved accurately when steps are taken to
limit analysis to viable bacterial cells. Furthermore, they sug-
gest that, when such steps are not taken, clinically important
outcomes may go undetected.
However, despite the ability of PMA treatment to limit
the contribution of non-viable bacteria to RT-PCR-based
enumeration of bacteria in clinical samples, it is also impor-
tant to consider some of the limitations of such a culture-
independent approach. For example, comparisons of bacterial
levels between samples can be affected by the presence of
PCR inhibitors or variations in DNA extraction efﬁciencies,
and the dynamic range of the assay [13]. Furthermore,
whereas the detection thresholds of RT-PCR and culture-
based assays for the detection of P. aeruginosa in CF sputum
have been shown to be indistinguishable [14], determination
of absolute bacterial numbers on the basis of RT-PCR
requires further validation. For this reason, the analysis per-
formed here was based on relative levels of P. aeruginosa in
pairwise comparisons across the treatment period.
The use of PMA treatment of samples has clear advanta-
ges in the context of the CF airways, but its beneﬁts may be
even more pronounced when applied to more simple scenar-
ios, such as the treatment of single-species acute infections
in normally sterile areas of the body. In such circumstances,
directly determining the relative success that an antibiotic
treatment would be of great clinical advantage, allowing mod-
iﬁcation of a therapeutic strategy if it was shown to be inef-
fective. Furthermore, because the detection of viable cells is
based on DNA, PMA treatment of clinical samples offers
advantages over systems that rely on the less stable mRNA
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FIG. 1. Pseudomonas aeruginosa loads in sputum sample before and
after intravenous antibiotics, with and without propidium monoazide
(PMA) treatment. Error bars represent standard error.
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or rRNA molecules [15,16], with lower sensitivity to poor
sample handling. The expansion of this work into many other
infective contexts is now important, as obtaining more accu-
rate data on antibiotic impact could be of signiﬁcant potential
beneﬁt to patients.
Transparency Declaration
The authors have no relevant afﬁliations or ﬁnancial involve-
ment with any organization or entity with a ﬁnancial interest
in or ﬁnancial conﬂict with the subject matter or materials
discussed in the manuscript.
References
1. Panousis K, Grigoris P, Butcher I, Rana B, Reilly JH, Hamblen DL.
Poor predictive value of broad-range PCR for the detection of
arthroplasty infection in 92 cases. Acta Orthop 2005; 76: 341–346.
2. Josephson KL, Gerba CP, Pepper IL. Polymerase chain reaction
detection of nonintact bacterial pathogens. Appl Environ Microbiol
1993; 59: 3513–3515.
3. Young G, Turner S, Davies JK, Sundqvist G, Figdor D. Bacterial DNA
persists for extended periods after cell death. J Endod 2007; 33:
1417–1420.
4. Castillo M, Martin-Orue SM, Manzanilla EG, Badiola I, Martin M, Gasa
J. Quantiﬁcation of total bacteria, enterobacteria and lactobacilli
populations in pig digesta by real-time PCR. Vet Microbiol 2006; 114:
165–170.
5. Nocker A, Sossa KE, Camper AK. Molecular monitoring of disinfec-
tion efﬁcacy using propidium monoazide in combination with quanti-
tative PCR. J Microbiol Methods 2007; 70: 252–260.
6. Nocker A, Sossa-Fernandez P, Burr MD, Camper AK. Use of propidi-
um monoazide for live/dead distinction in microbial ecology. Appl
Environ Microbiol 2007; 73: 5111–5117.
7. Rogers GB, Stressmann FA, Koller G, Daniels T, Carroll MP, Bruce
KD. Assessing the diagnostic importance of nonviable bacterial cells
in respiratory infections. Diagn Microbiol Infect Dis 2008; 62: 133–141.
8. Kobayashi H, Oethinger M, Tuohy MJ, Hall GS, Bauer TW. Improving
clinical signiﬁcance of PCR: use of propidium monoazide to distin-
guish viable from dead Staphylococcus aureus and Staphylococcus
epidermidis. J Orthop Res 2009; 27: 1243–1247.
9. Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, Bruce KD.
Characterization of bacterial community diversity in cystic ﬁbrosis lung
infections by use of 16s ribosomal DNA terminal restriction fragment
length polymorphism proﬁling. J Clin Microbiol 2004; 42: 5176–5183.
10. Shannon KE, Lee DY, Trevors JT, Beaudette LA. Application of real-
time quantitative PCR for the detection of selected bacterial patho-
gens during municipal wastewater treatment. Sci Total Environ 2007;
382: 121–129.
11. Robinson M, Bye PT. Mucociliary clearance in cystic ﬁbrosis. Pediatr
Pulmonol 2002; 33: 293–306.
12. Alenius H, Pakarinen J, Saris O et al. Contrasting immunological
effects of two disparate dusts—preliminary observations. Int Arch
Allergy Immunol 2009; 149: 81–90.
13. Zhang T, Fang HH. Applications of real-time polymerase chain reac-
tion for quantiﬁcation of microorganisms in environmental samples.
Appl Microbiol Biotechnol 2006; 70: 281–289.
14. Deschaght P, De Baere T, Van Simaey L et al. Comparison of the
sensitivity of culture, PCR and quantitative real-time PCR for the
detection of Pseudomonas aeruginosa in sputum of cystic ﬁbrosis
patients. BMC Microbiol 2009; 9: 244–250.
15. Rogers GB, Carroll MP, Serisier DJ et al. Bacterial activity in cystic
ﬁbrosis lung infections. Respir Res 2005; 6: 49–60.
16. Kobayashi H, Oethinger M, Tuohy MJ, Procop GW, Hall GS, Bauer
TW. Limiting false-positive polymerase chain reaction results: detec-
tion of DNA and mRNA to differentiate viable from dead bacteria.
Diagn Microbiol Infect Dis 2009; 64: 445–447.
PCR ampliﬁcation and high-resolution
melting curve analysis as a rapid diagnostic
method for genotyping members of the
Mycobacterium avium–intracellulare complex
E. Castellanos1,2, A. Aranaz1,2 and J. De Buck3
1) Centro de Vigilancia Sanitaria Veterinaria (VISAVET), 2) Departamento
de Sanidad Animal, Facultad de Veterinaria, Universidad Complutense de
Madrid, Madrid, Spain and 3) Department of Production Animal Health,
Faculty of Veterinary Medicine, University of Calgary, Calgary, Canada
Abstract
Some of the members of the Mycobacterium avium–intracellulare
(MAI) complex are recognized as human pathogens in both immu-
nocompromised and immunocompetent patients. The current
molecular methods that are available for genotyping the MAI com-
plex members can be both expensive and technically demanding.
In this report, we describe for the ﬁrst time the application of a
real-time PCR and high-resolution melt approach to differentiate
between the complex members by targeting a member of the Pro-
Pro-Glu gene family, MACPPE24. To this end, reference strains of
the M. avium subspecies andMycobacterium intracellulare were used
to optimize the technique. Then, this real-time PCR–high-resolu-
tion melt approach was used to distinguish ten M. avium ssp.
hominissuis ﬁeld isolates from the M. intracellulare reference strain.
Keywords: High-resolution melt, Mycobacterium avium
subspecies, Mycobacterium avium ssp. hominissuis, Mycobacterium
intracellulare, real-time PCR
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